Nautilus Biotechnology to join ARPA-H backed SEEDS consortium to study disease protein misfolding

Nautilus Biotechnology to join ARPA-H backed SEEDS consortium to study disease protein misfolding
Nautilus joins SEEDS for research

Nautilus Biotechnology announced its expected participation in SEEDS, a research consortium funded by the Advanced Research Projects Agency for Health (ARPA-H). The consortium is co-led by the Buck Institute and Georgetown and aims to study how disease-causing proteins misfold before irreversible cellular damage occurs.

This collaboration highlights Nautilus Biotechnology's commitment to advancing protein research in the biomedical field by contributing its proprietary measurement technology to cutting-edge health research initiatives.

Nautilus Biotechnology recently invited researchers to apply for an oncology grant to analyze AKT1 or EGFR proteoforms in 12 samples at no cost, according to a company announcement. The company has also detailed its Iterative Mapping method for profiling tau proteoforms in a new video based on its Nature Methods research. These initiatives reflect ongoing efforts to expand access to advanced protein measurement technologies.

This material may contain third-party opinions, none of the data and information on this webpage constitutes investment advice according to our Disclaimer. While we adhere to strict Editorial Integrity, this post may contain references to products from our partners.